Umkhiqizi Okuhlanzekile Okuphakeme 98% Peptides Powder Liraglutide CAS 204656-20-2 Peptides Powder in Vials amanani aphansi ama-peptides ubuhle Izinto zokusetshenziswa zezimonyo

I-Liraglutide (NN2211) iyi-agonist esebenza isikhathi eside ye-glucagon-like peptide-1. Imakethwa ngaphansi kwegama lomkhiqizo i-Victoza, iwumuthi ojovwayo owakhiwe ngabakwaNovo Nordisk ekwelapheni isifo sikashukela sohlobo 2. Ngo-2015, iNovo Nordisk yaqala ukuyimaketha e-US ngaphansi kwegama lomkhiqizo i-liraglutide njengendlela yokwelapha ukukhuluphala kubantu abadala okungenani abanesimo esisodwa esihlobene nesisindo.

Ukusetshenziswa Kwezokwelapha

I-Liraglutide iphuma kanye ngosuku yomjovo we-incretin (ihomoni ye-metabolic) i-glucagon-like peptide-1 (GLP-1), yokwelapha uhlobo 2 sikashukela noma ukukhuluphala.

Isifo sikashukela sohlobo 2

I-Liraglutide ithuthukisa ukulawulwa kweglucose yegazi. Ibambezela ukuphuma kwesisu, nokucindezela ukukhishwa kwe-prandial glucagon.

Ngokufana namadigri ahlukahlukene namanye ama-GLP-1 receptor agonists, i-liraglutide inezinzuzo kunezinye izindlela zokwelapha zendabuko zohlobo 2 lwesifo sikashukela:

Inamandla okuvimbela i-apoptosis futhi ikhuthaze ukukhiqizwa kabusha kwamaseli e-beta (okubonwa ezifundweni zezilwane).

Yehlisa isifiso sokudla futhi ivimbele ukuzuza kwesisindo somzimba, njengoba kukhonjisiwe ocwaningweni lwekhanda nekhanda ngokumelene ne-glimepiride.

Yehlisa amazinga e-triglyceride egazini.

Ukukhuluphala ngokweqile

I-Liraglutide igunyazwe njengesijobelelo sokujova ekudleni okunekhalori encishisiwe kanye nokwanda kokuzivocavoca umzimba kokulawulwa kwesisindo esingamahlalakhona ezigulini zabantu abadala. Imibandela eshiwo inkomba yokuqala yesisindo somzimba (BMI) engu-30 kg/m2 noma ngaphezulu (okukhuluphala), noma 27 kg/m2 noma ngaphezulu (isisindo esiningi), lapho kukhona okungenani isimo esisodwa esihlobene nesisindo somzimba (isb. umfutho wegazi ophakeme), uhlobo 2 sikashukela i-mellitus, noma i-dyslipidemia). Ngasekupheleni kuka-2014, idatha yabikwa evela ocwaningweni lwe-SCALE™ Obesity and Prediabetes, okuyisivivinyo esingahleliwe, esingaboni kabili, esilawulwa yi-placebo, esilawulwa yizizwe eziningi kubantu abangenaso isifo sikashukela abanokukhuluphala kanye nabantu abangenaso isifo sikashukela abakhuluphele ngokweqile nge-comorbidities. Kulesi sivivinyo sesigaba sesi-3a, kwakukhona ababambiqhaza abangu-3,731 abangahleliwe ekwelashweni nge-liraglutide 3 mg noma i-placebo, kokubili kuhlanganiswe nokudla nokuzivocavoca. Labo abaqede uhlolo lwamasonto angama-56 bathole ukwehla kwesisindo esimaphakathi esingu-9.2%, okuzoqhathaniswa nokwehliswa ngo-3.5% eqenjini le-placebo.